Clinical Trials

81 results for Prostate Cancer


Phase I Feasibility Trial of Stereotactic Re-irradiation of Prostate Cancer Recurrence Within the Definitively Irradiated Prostate

  • Condition: Locally Recurrent Prostate Cancer
  • Intervention: Radiation: Stereotactic Body Radiotherapy
  • Study ID: NCT03073278
View Trial

A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Apalutamide, Drug: Degarelix, Drug: Abiraterone Acetate, Drug: Prednisone
  • Study ID: NCT03009981
View Trial

A Phase II Randomized, Open-Label, Two-Arm Study of a Low-Fat Diet With Fish Oil Capsules vs. a Control Group in Men on Active Surveillance for Prostate Cancer

  • Condition: Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
  • Intervention: Behavioral: behavioral dietary intervention, Behavioral: behavioral dietary intervention, Dietary Supplement: omega-3 fatty acid, Other: laboratory biomarker analysis
  • Study ID: NCT02176902
View Trial

A Feasibility and Safety Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Non-Resectable Pancreatic Cancer

  • Condition: Non-Resectable Pancreatic Cancer
  • Intervention: Biological: BPX-601, Drug: Rimiducid
  • Study ID: NCT02744287
View Trial

Cystoprostatectomy Versus Radiotherapy Combined With Androgen Deprivation Therapy for the Treatment of Clinical T4 Prostate Cancer With Bladder Invasion: a Multicentre, Prospective, Open, Randomized Clinical Trial

  • Condition: Prostate Cancer
  • Intervention: Procedure: Cystoprostatectomy, Radiation: external beam radiotherapy
  • Study ID: NCT03482089
View Trial

Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)

  • Condition: Prostate Cancer, Localized Malignant Neoplasm
  • Intervention: Radiation: Stereotactic Body Radiation Therapy (SBRT)
  • Study ID: NCT01766492
View Trial

A Randomized Clinical Trial of Exercise vs. Usual Care Among Men Opting for Active Surveillance for Prostate Cancer

  • Condition: Localized Prostate Cancer, Active Surveillance for Prostate Cancer
  • Intervention: Behavioral: Exercise
  • Study ID: NCT02435472
View Trial

Study of 18F-DCFPyL PET/CT, for Detection of Radiological Progression in Patients With Metastatic (M+) and Non-metastatic (M0) Castration Resistant Prostate Cancer Receiving Standard Androgen Receptor Targeted Treatment

  • Condition: Prostate Cancer
  • Intervention: Drug: 18F-DCFPyL Injection
  • Study ID: NCT03800784
View Trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IV Study of Apalutamide in Chinese Subjects With Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)

  • Condition: Prostatic Neoplasms
  • Intervention: Drug: Apalutamide, Drug: Placebo, Drug: Androgen-deprivation Therapy (ADT)
  • Study ID: NCT04108208
View Trial

A Phase I Study of 68GA-PSMA-11 PET Imaging for Biochemically Recurrent Prostate Cancer

  • Condition: Biochemically Recurrent Prostate Carcinoma
  • Intervention: Drug: Gallium Ga 68-labeled PSMA-11, Procedure: Positron Emission Tomography
  • Study ID: NCT04216134
View Trial

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

  • Condition: Stage II Prostate Adenocarcinoma
  • Intervention: Radiation: Intensity-Modulated Radiation Therapy (IMRT), Radiation: Stereotactic Body Radiation Therapy (SBRT)
  • Study ID: NCT03367702
View Trial

Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate

  • Condition: Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Neuroendocrine Neoplasm, Pro
  • Intervention: Drug: Carboplatin, Drug: Cisplatin, Drug: Docetaxel, Drug: Etoposide, Biological: Pembrolizumab
  • Study ID: NCT03582475
View Trial

Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Pembrolizumab, Drug: Enzalutamide
  • Study ID: NCT03753243
View Trial

A Phase 1/2 Study of Ibrutinib as Neoadjuvant Therapy in Patients With Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Ibrutinib
  • Study ID: NCT02643667
View Trial

Phase 2, Multicenter, Prospective Cohort Study, Estimating the Efficacy of Focused HIFU Therapy in Patients With Localized Intermediate Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies, Biological: blood test, Biological: urine test
  • Study ID: NCT03568188
View Trial

A Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy in Localized Prostate Cancer

  • Condition: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
  • Intervention: Radiation: High-Dose Rate Brachytherapy, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Procedure: Stereotactic Ablative Radiotherapy
  • Study ID: NCT04253483
View Trial

PSMA-PET Registry for Recurrent Prostate Cancer Following Radical Prostatectomy

  • Condition: Recurrent Prostate Cancer
  • Intervention: Diagnostic Test: [18F]-DCFPyL PET/ CT scan (PSMA PET)
  • Study ID: NCT03718260
View Trial

Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-guided Transurethral Ultrasound Ablation for Localized Prostate Cancer

  • Condition: Localized Prostate Cancer
  • Intervention: Device: MRI-TULSA
  • Study ID: NCT03814252
View Trial

Hypofractionated Radiosurgery for Localised Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Radiation: Hypofractionated Radiosurgery
  • Study ID: NCT03795337
View Trial

Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients

  • Condition: Prostate Cancer
  • Intervention: Drug: Darolutamide(Nubeqa, BAY1841788)
  • Study ID: NCT04122976
View Trial

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvag

  • Condition: Prostate Cancer
  • Intervention: Drug: Darolutamide, Drug: Placebo oral tablet, Drug: Luteinizing Hormone-Releasing Hormone Analog, Radiation: External Beam Radiotherapy
  • Study ID: NCT04136353
View Trial

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

  • Condition: Prostatic Neoplasms
  • Intervention: Drug: Apalutamide, Drug: Androgen Deprivation Therapy (ADT), Drug: Placebo
  • Study ID: NCT03767244
View Trial

Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies
  • Study ID: NCT03531099
View Trial

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer

  • Condition: Prostate Cancer, Prostate Disease
  • Intervention: Drug: Nivolumab, Radiation: Brachytherapy, Radiation: External Beam Radiation Therapy, Drug: Androgen Deprivation Therapy
  • Study ID: NCT03543189
View Trial

68Ga-PSMA-11 PET in Patients With Prostate Cancer

  • Condition: Biochemically Recurrent Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
  • Study ID: NCT04777071
View Trial

A Phase 2 Study of Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Nivolumab
  • Study ID: NCT03637543
View Trial

The BARCODE 1 Study: The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.

  • Condition: Prostate Cancer
  • Intervention: Genetic: Genetic SNP profiling, Other: Prostate cancer screening, Procedure: MRI Scan, Procedure: Prostate biopsy
  • Study ID: NCT03857477
View Trial

Protocol for the Development of a Machine Learning Model for Prostate Cancer Treatment Planning

  • Condition: Prostate Cancer, Artificial Intelligence, Radiotherapy
  • Study ID: NCT04441775
View Trial

A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: 68Ga RM2, Drug: 68Ga-PSMA-11, Device: Investigational PET scanner coils and software
  • Study ID: NCT03809078
View Trial

A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy

  • Condition: Prostate Cancer
  • Intervention: Drug: 68-Ga RM2, Drug: 68-Ga PSMA11, Device: Investigational software and coils in PET/MR Scan, Procedure: PET/MRI
  • Study ID: NCT03949517
View Trial

A Phase 2 Comparison Study of 68Ga-PSMA-HBED-CC Positron Emission Tomography (PET)/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: PET/MRI with Gallium-68 labeled PSMA-HBED-CC, Drug: Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC, Drug: PET/CT with Gallium-68 labeled PSMA-HBED-CC
  • Study ID: NCT03439033
View Trial